What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, we are providing a lifeline of access to innovative medicines under review or not yet approved locally when no other treatment options are available.

State-of-the-art Novartis manufacturing facility in Indianapolis fortifies the foundation of an entirely new paradigm in pharmaceutical drug delivery.

John Tsai, Head of Global Drug Development and Chief Medical Officer, describes how he balances innovation and patient needs.

Inside the hunt for new antivirals to combat the current pandemic and to prepare for future ones.

Combinations of drugs could hold the key to overcoming some of the biggest challenges in lung and other cancers.

The race is on to find a new treatment before resistance to today’s drugs becomes widespread.

Jay Bradner discusses his vision for an open framework of scientific discovery at Novartis.

Umbilical cords are a potentially life-saving source of blood stem cells for people with leukemia and other diseases. But there aren’t enough cells to meet demand. Now an experimental treatment offers hope for a solution.